Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Short Candidates -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (786)	2/1/2006 10:51:25 AM
From: tuck	Respond to of 897

OTOH, not sure how much TRMS' R&D is costing them. Roche covering most of it? Anyhow, thanks to George for this: Message 22120676 Which includes Piper's take on TRMS. I'd guess there was another bulk sale of Fuzeon. Perhaps something was said on the CC. Cheers, Tuck

To: tuck who wrote (786)	3/10/2006 12:44:36 PM
From: tuck	Read Replies (1) \| Respond to of 897

Trimeris slaughters estimates of a one penny loss by 18 cents, and expects continued profitability in '06. Analysts' models were way off here, because Fuzeon sales were as expected. Trimeris claims to have reduced expenses, and I wonder if they hit a different royalty tier when Fuzeon went beyond the $200 million mark. Anyhow, the stock is flirting with fireworks status, and I'm glad I did not short it recently. Steve, nice call on AFFX. More, please. >>MORRISVILLE, N.C.--(BUSINESS WIRE)--March 9, 2006--Trimeris, Inc. (NASDAQ: TRMS - News) today announced 2005 financial results reporting an 80% reduction in losses from prior year and the first profitable quarter for the company. These results were primarily driven by record worldwide sales of FUZEON, reaching $208 million, a growth of 54% - in its second full year since launch. The Company expects continued profitability and significant growth for 2006 through expansion in FUZEON sales and strong fiscal management with continued investment in its pipeline assets. The Company reported a net profit for the fourth quarter of 2005 of $3.8 million, or $0.17 per share, compared with a loss of $5.7 million ($0.27 per share) in the fourth quarter of 2004. For the year ended 2005, the Company's net loss totaled $8.1 million ($0.37 per share), compared with a loss of $40.1 million ($1.86 per share) for 2004. The decrease in net loss for 2005 compared to 2004 is primarily due to the increase in gross profit from the sale of FUZEON and decreases in operating expenses. Cash, cash equivalents and investment securities available-for-sale totaled $36.9 million at December 31, 2005 compared to $48.4 million at December 31, 2004. "Attaining profitability is a significant and transforming event for Trimeris," said Steven D. Skolsky, Chief Executive Officer of Trimeris. Mr. Skolsky added, "Continued investment in the growth of FUZEON, efficient use of resources, and the progression of the next generation fusion inhibitor program will be the foundation for significant growth and continued profitability through 2006." A live webcast of our conference call on March 9, 2006 at 5:00 p.m. Eastern Time will be available at trimeris.com. << snip Cheers, Tuck